vs
中国太平保险控股（IGIC）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是中国太平保险控股的1.9倍（$772.1M vs $403.8M），中国太平保险控股净利率更高（26.0% vs 12.7%，领先13.3%）
中国太平保险控股有限公司（前身为中国保险国际控股有限公司）是一家中国保险集团，虽在香港注册成立，但背靠中国中央政府，属红筹企业，在保险行业拥有深厚的资源积累与市场影响力。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
IGIC vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.9倍
$403.8M
净利率更高
IGIC
高出13.3%
12.7%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $403.8M | $772.1M |
| 净利润 | $105.1M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | — | 14.5% |
| 净利率 | 26.0% | 12.7% |
| 营收同比 | — | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | $2.31 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IGICRVTY
| Q4 25 | — | $772.1M | ||
| Q3 25 | $403.8M | $698.9M | ||
| Q2 25 | $261.9M | $720.3M | ||
| Q1 25 | — | $664.8M | ||
| Q4 24 | — | $729.4M | ||
| Q3 24 | $369.6M | $684.0M | ||
| Q2 24 | $265.8M | $691.7M | ||
| Q1 24 | — | $649.9M |
净利润IGICRVTY
| Q4 25 | — | $98.4M | ||
| Q3 25 | $105.1M | $46.7M | ||
| Q2 25 | $61.4M | $53.9M | ||
| Q1 25 | — | $42.2M | ||
| Q4 24 | — | $94.6M | ||
| Q3 24 | $-134.4M | $94.4M | ||
| Q2 24 | $70.7M | $55.4M | ||
| Q1 24 | — | $26.0M |
毛利率IGICRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率IGICRVTY
| Q4 25 | — | 14.5% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | 24.2% | 12.6% | ||
| Q1 25 | — | 10.9% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | — | 14.3% | ||
| Q2 24 | -73.3% | 12.4% | ||
| Q1 24 | — | 6.8% |
净利率IGICRVTY
| Q4 25 | — | 12.7% | ||
| Q3 25 | 26.0% | 6.7% | ||
| Q2 25 | 23.5% | 7.5% | ||
| Q1 25 | — | 6.4% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | -36.4% | 13.8% | ||
| Q2 24 | 26.6% | 8.0% | ||
| Q1 24 | — | 4.0% |
每股收益（稀释后）IGICRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | $2.31 | $0.40 | ||
| Q2 25 | $1.36 | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | $1.82 | $0.77 | ||
| Q2 24 | $1.55 | $0.45 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $244.7M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $654.8M | $7.3B |
| 总资产 | $2.0B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IGICRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | $244.7M | $931.4M | ||
| Q2 25 | $164.8M | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | $219.2M | $1.2B | ||
| Q2 24 | $237.3M | $2.0B | ||
| Q1 24 | — | $1.7B |
股东权益IGICRVTY
| Q4 25 | — | $7.3B | ||
| Q3 25 | $654.8M | $7.4B | ||
| Q2 25 | $662.3M | $7.6B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.7B | ||
| Q3 24 | $540.5M | $7.9B | ||
| Q2 24 | $588.2M | $7.9B | ||
| Q1 24 | — | $7.8B |
总资产IGICRVTY
| Q4 25 | — | $12.2B | ||
| Q3 25 | $2.0B | $12.1B | ||
| Q2 25 | $2.1B | $12.4B | ||
| Q1 25 | — | $12.4B | ||
| Q4 24 | — | $12.4B | ||
| Q3 24 | $1.8B | $12.8B | ||
| Q2 24 | $2.0B | $13.4B | ||
| Q1 24 | — | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流IGICRVTY
| Q4 25 | — | $182.0M | ||
| Q3 25 | — | $138.5M | ||
| Q2 25 | $27.2M | $134.3M | ||
| Q1 25 | — | $128.2M | ||
| Q4 24 | — | $174.2M | ||
| Q3 24 | — | $147.9M | ||
| Q2 24 | $120.7M | $158.6M | ||
| Q1 24 | — | $147.6M |
自由现金流IGICRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | $26.8M | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | $119.8M | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率IGICRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | 10.2% | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | 45.1% | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度IGICRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | 0.2% | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | 0.3% | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率IGICRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | 0.44× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | 1.71× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IGIC
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
